Moriguchi Shigeki, Shioda Norifumi, Han Feng, Narahashi Toshio, Fukunaga Kohji
Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
J Neurochem. 2008 Aug;106(3):1092-103. doi: 10.1111/j.1471-4159.2008.05440.x. Epub 2008 Apr 28.
Nefiracetam is a pyrrolidine-related nootropic drug exhibiting various pharmacological actions such as cognitive-enhancing effect. We previously showed that nefiracetam potentiates NMDA-induced currents in cultured rat cortical neurons. To address questions whether nefiracetam affects NMDA receptor-dependent synaptic plasticity in the hippocampus, we assessed effects of nefiracetam on NMDA receptor-dependent long-term potentiation (LTP) by electrophysiology and LTP-induced phosphorylation of synaptic proteins by immunoblotting analysis. Nefiracetam treatment at 1-1000 nM increased the slope of fEPSPs in a dose-dependent manner. The enhancement was associated with increased phosphorylation of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptor through activation of calcium/calmodulin-dependent protein kinase II (CaMKII) without affecting synapsin I phosphorylation. In addition, nefiracetam treatment increased PKCalpha activity in a bell-shaped dose-response curve which peaked at 10 nM, thereby increasing phosphorylation of myristoylated alanine-rich protein kinase C substrate and NMDA receptor. Nefiracetam treatment did not affect protein kinase A activity. Consistent with the bell-shaped PKCalpha activation, nefiracetam treatment enhanced LTP in the rat hippocampal CA1 region with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with CaMKII and PKCalpha activation with concomitant increases in phosphorylation of their endogenous substrates except for synapsin I. These results suggest that nefiracetam potentiates AMPA receptor-mediated fEPSPs through CaMKII activation and enhances NMDA receptor-dependent LTP through potentiation of the post-synaptic CaMKII and protein kinase C activities. Together with potentiation of nicotinic acetylcholine receptor function, nefiracetam-enhanced AMPA and NMDA receptor functions likely contribute to improvement of cognitive function.
奈非西坦是一种与吡咯烷相关的促智药,具有多种药理作用,如认知增强作用。我们之前表明,奈非西坦可增强培养的大鼠皮质神经元中NMDA诱导的电流。为了解决奈非西坦是否影响海马体中NMDA受体依赖性突触可塑性的问题,我们通过电生理学评估了奈非西坦对NMDA受体依赖性长时程增强(LTP)的影响,并通过免疫印迹分析评估了LTP诱导的突触蛋白磷酸化。1-1000 nM的奈非西坦处理以剂量依赖性方式增加了场兴奋性突触后电位(fEPSP)的斜率。这种增强与通过激活钙/钙调蛋白依赖性蛋白激酶II(CaMKII)增加α-氨基-3-羟基-5-甲基异恶唑-4-丙酸(AMPA)受体的磷酸化有关,而不影响突触素I的磷酸化。此外,奈非西坦处理以钟形剂量反应曲线增加蛋白激酶Cα(PKCα)活性,在10 nM时达到峰值,从而增加肉豆蔻酰化富含丙氨酸的蛋白激酶C底物和NMDA受体的磷酸化。奈非西坦处理不影响蛋白激酶A活性。与钟形PKCα激活一致,奈非西坦处理以相同的钟形剂量反应曲线增强了大鼠海马体CA1区的LTP。此外,奈非西坦诱导的LTP增强与CaMKII和PKCα激活密切相关,同时其内源底物(突触素I除外)的磷酸化增加。这些结果表明,奈非西坦通过CaMKII激活增强AMPA受体介导的fEPSP,并通过增强突触后CaMKII和蛋白激酶C活性增强NMDA受体依赖性LTP。与烟碱型乙酰胆碱受体功能增强一起,奈非西坦增强的AMPA和NMDA受体功能可能有助于改善认知功能。